News

From a gravel parking area to a modern, historic village center. BGPartner congratulates Stefan Kunz on the successful launch of a unique building project in Schwarzenburg. Using a workshop process, the architectural firm Ductus Studio, the Office for Municipalities, the AGR spatial planning department, and the Cantonal Office for the Protection of Historical Monuments were from the very beginning on, synergistically involved in the project.

Thanks to his wealth of experience as a lawyer in the field of building and planning law, Stefan Kunz, Chairman of the Board of Directors of Dorfzentrum Linde Schwarzenburg AG,  was able to advise the parties involved accordingly, manage the project and, through his negotiating skills, offer all stakeholders a satisfactory solution.

Enjoy reading the article from the Freiburger Nachrichten. Go to the article.  

BGPartner is pleased to welcome Nicolas Vogt (Trainee) to the Berne team as of March 1, 2022. Further information on Nicolas Vogt and our entire team can be found here.

BGPartner is pleased to welcome Geremia Stüssi (Trainee) to the Zurich team as of March 1, 2022. Further information on Geremia Stüssi and our entire team can be found here.

BGPartner is pleased to welcome Tanja Aebersold to the Berne team as of September 1, 2021. Further information on Tanja Aebersold and our entire team can be found here.

BGPartner advises Memo Therapeutics Ltd on its CHF 37 Million Series B Financing Round

BGPartner advises Memo Therapeutics Ltd, an innovator in the field of antibody discovery and development, on its successfully closing of a CHF 37 million series B financing round following an oversubscribed CHF 23 million extension. BGPartner assisted Memo Therapeutics Ltd in the negotiations and advised on all Swiss legal matters with regard to this transaction.

The strategic and financial investors of this series B financing include Swisscanto (lead investor), Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank and other investors. The roots of investor Adjuvant Capital date back to efforts by the Bill & Melinda Gates Foundation and J.P. Morgan to test the idea of building an impact investment portfolio from the most promising drug, vaccine, diagnostic, and medical device technologies that address high-burden public health challenges, neglected infectious diseases, and maternal/infant mortality.

Memo Therapeutics Ltd intends to use the proceeds to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients. In addition, Memo Therapeutics Ltd will use the funding to develop and expand its antibody pipeline and secure new partnering agreements.

Furthermore, Memo Therapeutics Ltd recently announced that it has received a CHF 10.5 million commitment from the Swiss Federal Funding Programme for COVID-19 medicines to advance COVAB 36, a potent, fully human monoclonal antibody administered via inhalation for the treatment of SARS-CoV-2 infections, into clinical development.

The BGPartner team assisting Memo Therapeutics Ltd in legal and negotiation matters is led by Oliver Gnehm (Partner) and further consists of Victoria Marty (Associate) and Thomas Gysin (Senior Associate).

More information about our negotiation expertise can be found here.

BGPartner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital". More information can be found here.